Danaher (DHR) Dividend Yield & History

DHR$233.02+0.86 +0.37%
Medical - Diagnostics & ResearchLarge Cap
Compare
Market cap$163.94BEnterprise value$185.95BRevenue (TTM)$25.61BMarket positionTop 25%

Score

44
Bearish
Value
32
Quality
51
Growth
50
$233.02Price
$163.94BMarket cap
37.85P/E
25.63Forward P/E
0.65%Dividend yield

Yield is based on dividends paid in the past 12 months. 2026 isn't counted in streaks until the year ends.

$1.52 a share over the past year is a 0.65% yield on Danaher Corporation at $233.02.

Danaher raised its yearly dividend every year from 2013 to 2025.

A quarterly increase on 27 March 2026 took Danaher from $0.32 to $0.40, up 25%.

Danaher returned 23% of earnings as dividends last year.

Danaher distributes its dividend each quarter.

The next ex-dividend date for Danaher hasn't been announced yet.

The five-year growth rate of the Danaher dividend is 14.3% a year.

Our records cover 135 payments from 1993 to 2026.

At today's yield, $10,000 invested would receive about $65 a year in dividends before tax, if payments stay the same. Dividends can be cut.

Learn: How to read a dividend

Full DHR quote · Forecast · Academy

Questions

When did DHR last raise the dividend?

$0.32 was followed by $0.40 on 27 March 2026.

How often does DHR pay a dividend?

Danaher shareholders were paid 4 times in the past year.

How many years has DHR raised the dividend?

In 5 of the last 5 years. 2025 totalled $1.23 a share.

What is the DHR dividend yield?

DHR is on a 0.65% dividend yield.

Danaher (DHR) Dividend Yield & History

DHR price $233.02 +0.86 +0.37%

Ticker
DHR
Price
$233.02
Change
+0.86 +0.37%
Market cap
$163.94B
P/E
37.85
Forward P/E
25.63
Dividend yield
0.65%
Beta
0.80
Sector
Healthcare
Industry
Medical - Diagnostics & Research
Stocklytics score
44
Value
32
Quality
51
Growth
50

Stocklytics score rationale: value 32, quality 51, growth 50.

AI Score 75. Danaher Corporation has a solid market capitalization of $163.25 billion and a price of $232.23, indicating strong investor confidence. However, its price-to-earnings ratio of approximately 37.95 suggests it may be overvalued relative to its earnings, despite a healthy net profit margin of 16.91% and consistent revenue growth in recent quarters

Insights · Dividends · Forecast · Financials · Learn

Stocklytics home · Screener